IDEXX Laboratories, Inc. IDXX
- Market cap
- $40.2B
- P/E
- 36.2×
Follow IDXX
IDEXX Laboratories, Inc. (IDXX) EV/EBITDA
As of 25 September 2026, IDEXX Laboratories, Inc. (IDXX) trades at a EV/EBITDA of 25.6×. Over the past ten years it has ranged from 16.9× (January 2016) to 63.2× (August 2021); the current reading is higher than 16% of that period. That is in line with the Diagnostics & Research industry median of 25.2× and above the Healthcare sector median of 10.4×.
EV/EBITDA, daily
Annual
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2025 | 36.3× | 32.78% |
| FY2024 | 27.4× | (27.50%) |
| FY2023 | 37.7× | 10.20% |
| FY2022 | 34.2× | (37.51%) |
| FY2021 | 54.8× | 0.31% |
| FY2020 | 54.6× | 49.61% |
| FY2019 | 36.5× | 26.09% |
| FY2018 | 29.0× | 2.73% |
| FY2017 | 28.2× | 12.52% |
| FY2016 | 25.1× | 32.37% |
Quarterly
| Period | EV/EBITDA | Change |
|---|---|---|
| Jun 2026 | 25.9× | (10.41%) |
| Mar 2026 | 28.9× | (20.33%) |
| Dec 2025 | 36.3× | 2.04% |
| Sep 2025 | 35.6× | 14.02% |
| 42 more quarters | Free account |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| NTRA Natera, Inc. compare | n/m |
| GH Guardant Health, Inc. compare | n/m |
| DGX Quest Diagnostics Incorporated compare | 14.1× |
| IQV IQVIA Holdings Inc. compare | 17.3× |
| MTD Mettler-Toledo International, Inc. compare | 24.9× |
| IDXX IDEXX Laboratories, Inc. | 25.6× |
| A Agilent Technologies, Inc. compare | 26.5× |
| ILMN Illumina, Inc. compare | 36.0× |
| WAT Waters Corporation compare | 49.8× |
| Diagnostics & Research industry median | 25.2× |
| Healthcare sector median | 10.4× |
| Market median | 11.0× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)
More on IDXX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement